
Akums Drugs & Pharmaceuticals Ltd. (AKUMS) Share Price Hits Fresh 52-Week High
Updated: 11 Aug 2026 • 10:19 am
Posted by:

Akums Drugs & Pharmaceuticals Ltd. traded at Rs 755.65, up 3.34% today, after hitting a fresh 52-week high of Rs 761. The company’s market capitalisation stood at Rs 10,962.49 crore.
Akums Drugs & Pharmaceuticals Ltd. Share Price traded at Rs 755.65 on 11 August 2026, up Rs 24.4 or 3.34% from the previous close of Rs 731.25, after touching a fresh 52-week high of Rs 761. With a market capitalisation of Rs 10,962.49 crore, the stock has moved into focus in today’s Stock Market Today and Share Market Today activity as investors track fresh one-year highs across the Indian Stock Market.
The verified data confirms the price event clearly: the stock opened at Rs 720.35, moved through an intraday range of Rs 720.35 to Rs 761, and was trading close to the session peak when this Univest article was prepared at 11 August 2026 at 10:16 AM IST. Turnover stood at Rs 1.24 crore with current volume of 16,360 shares, signalling that the move is attracting attention in Akums Drugs & Pharmaceuticals Ltd. Stock News and broader Market News coverage.
What the supplied data establishes is the breakout in price, not a company-specific catalyst. That still makes the move relevant because Akums Drugs & Pharmaceuticals Ltd. Share Price is now at a yearly high while trading in the Healthcare sector with valuation and profitability metrics that can be compared directly with sector and peer benchmarks. For investors following Akums Drugs & Pharmaceuticals Ltd. Share Price Today, the next step is to assess whether the current move is supported by fundamentals, relative positioning and sector context. Univest examines those verified data points below.
Akums Drugs & Pharmaceuticals Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 755.65 |
| Previous Close | Rs 731.25 |
| Today's Change | +Rs 24.4 (+3.34%) |
| Day Open | Rs 720.35 |
| Fresh 52-Week High | Rs 761 |
| Day Low | Rs 720.35 |
| Current Volume | 16,360 |
| Turnover | Rs 1.24 crore |
| Market Capitalisation | Rs 10,962.49 crore |
Akums Drugs & Pharmaceuticals Ltd. (AKUMS) traded at Rs 755.65. versus the previous close of Rs 731.25, a rise of 3.34%. The stock opened at Rs 720.35, reached Rs 761, touched Rs 720.35. Reported volume was 16,360.
Akums Drugs & Pharmaceuticals Ltd. Share Price Today shows a clear intraday strength pattern, with the stock opening at Rs 720.35, staying above that level as the day’s low, and then advancing to a fresh 52-week high of Rs 761 before trading at Rs 755.65. The day gain of Rs 24.4, or 3.34%, versus the previous close of Rs 731.25 captures the exact move that has placed the stock among 52 Week High Stocks and Market Movers.
The session range also matters. Because the day low and opening price were both Rs 720.35, the stock did not break below its opening level during the observed session. It then climbed by Rs 40.65 from the day low to the intraday high of Rs 761. Trading close to the session peak suggests sustained buying interest during the morning rather than a brief spike. In Akums Drugs & Pharmaceuticals Ltd. Share News terms, that is the most important fact from today’s price action.
Turnover of Rs 1.24 crore and current volume of 16,360 shares show active participation, although the supplied data does not establish an average-volume benchmark or a company-specific trigger. Even so, for readers searching Akums Drugs & Pharmaceuticals Ltd. Share Price Live, the verified picture is straightforward: the stock moved decisively above prior trading levels and registered a fresh 52-week peak. That naturally shifts attention from pure Price Action to valuation and financial quality.
Akums Drugs & Pharmaceuticals Ltd. (AKUMS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 10,962.49 crore |
| P/E Ratio | 40.09x |
| P/B Ratio | 9.77x |
| ROE | 28.21% |
| ROCE | 26.35% |
Akums Drugs & Pharmaceuticals Ltd. was valued at a P/E ratio of 40.09x, a P/B ratio of 9.77x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 40.09x |
| Benchmark Median P/E | 20.84x |
| Benchmark Average P/E | 76.55x |
| Benchmark P/E Range | 0x to 3,396.3x |
| Company P/B Ratio | 9.77x |
| Benchmark Median P/B | 1.93x |
| Company ROE | 28.21% |
| Benchmark Median ROE | 10.77% |
| Company ROCE | 26.35% |
| Benchmark Median ROCE | 13.35% |
| Company Market Capitalisation | Rs 10,962.49 crore |
| Benchmark Median Market Cap | Rs 142.3 crore |
Akums Drugs & Pharmaceuticals Ltd. (AKUMS) is classified under sector: Healthcare.
Akums Drugs & Pharmaceuticals Ltd. (AKUMS) has a P/E ratio of 40.09x, which is above the benchmark median of 20.84x, a difference of +92.37%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Akums Drugs & Pharmaceuticals Ltd. (AKUMS) has a ROE of 28.21%, which is above the benchmark median of 10.77%, a difference of +161.93%. Akums Drugs & Pharmaceuticals Ltd. (AKUMS) has a ROCE of 26.35%, which is above the benchmark median of 13.35%, a difference of +97.38%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd. | KPL | 2,707.2 | 40.09 | 9.77 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,631.45 | 66.92 | 10.59 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,601.85 | 34.14 | 7.04 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,513.58 | 181.97 | 3.36 | 13.9 | 12.97 |
| NGL Fine-Chem Ltd. | NGLFINE | 2,118.6 | 44.48 | 6.5 | 27.9 | 33.91 |
Akums Drugs & Pharmaceuticals Ltd. (AKUMS) has a P/E ratio of 40.09x compared with the displayed peer median of 44.48x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 18.65% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 22.17%, providing a capital-efficiency comparison. Akums Drugs & Pharmaceuticals Ltd. (AKUMS) has a market capitalisation of Rs 10,962.49 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Akums Drugs & Pharmaceuticals Ltd.
This stock is attracting attention because verified data points across price, valuation and sector context are aligning around a fresh yearly high. For Akums Drugs & Pharmaceuticals Ltd. Stock Performance watchers, the focus is on what is already visible in the numbers.
- Fresh price milestone: the stock hit a new 52-week high of Rs 761 and was trading at Rs 755.65, up 3.34% on the day.
- Strong intraday move: it opened at Rs 720.35, which also marked the day low, and climbed steadily toward the session high.
- Large company context: market capitalisation of Rs 10,962.49 crore is well above the sector benchmark median and average.
- Profitability support: ROE of 28.21% and ROCE of 26.35 are both above same-sector medians and averages.
- Valuation in focus: P/E of 40.09 and P/B of 9.77 indicate the stock is not cheaply valued relative to sector medians.
- Peer relevance: compared with the supplied peer set, Akums combines larger scale with generally stronger or competitive profitability.
About Akums Drugs & Pharmaceuticals Ltd.
Akums Drugs & Pharmaceuticals Ltd. operates in the Healthcare sector. Beyond that sector classification, the supplied peer context places the company alongside businesses connected with Pharmaceuticals & Drugs and broader healthcare services. That makes Akums relevant for investors screening both healthcare and pharma-linked listed names.
The most reliable business context available in the supplied dataset comes from market positioning rather than descriptive text. Akums has a market capitalisation of Rs 10,962.49 crore, which is much larger than the peer companies listed in the provided comparison set, where market caps range from Rs 2,118.6 crore to Rs 2,707.2 crore for the selected names. Its profitability metrics, with ROE of 28.21% and ROCE of 26.35, also place it above the broader sector medians and averages. In practical terms, that means the company is drawing attention not just because of a fresh 52 Week High, but because it sits at the intersection of scale, premium valuation and strong return ratios within Healthcare. Readers looking for Akums Drugs & Pharmaceuticals Ltd. Company News and Akums Drugs & Pharmaceuticals Ltd. Market Cap context can use these verified figures as the clearest current snapshot.
Track Akums Drugs & Pharmaceuticals Ltd. Share Price on Univest
Use Akums Drugs & Pharmaceuticals Ltd. (AKUMS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors who want to follow Akums Drugs & Pharmaceuticals Ltd. Share Price more closely can track live share price moves, 52-week levels, market cap, valuation ratios, peer comparisons and broader market insights on Univest. The platform also helps users monitor Akums Drugs & Pharmaceuticals Ltd. Share Price Today alongside stock analysis screens, sector comparisons and structured company data.
For those researching Akums Drugs & Pharmaceuticals Ltd. Stock News, Univest can be used to watch fresh highs, price updates, fundamental ratios and changes in how the stock compares with sector benchmarks over time. That is especially useful when a stock is making a new one-year high and investors want a factual dashboard rather than headline-driven interpretation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the latest Akums Drugs & Pharmaceuticals Ltd. Share Price today?
Ans. Akums Drugs & Pharmaceuticals Ltd. Share Price was Rs 755.65 at the time of this update. The stock was up Rs 24.4 or 3.34% from the previous close of Rs 731.25 after touching a fresh 52-week high.
What was the fresh 52-week high for Akums Drugs & Pharmaceuticals Ltd.?
Ans. The stock touched a fresh 52-week high of Rs 761 in intraday trade on 11 August 2026. It later traded at Rs 755.65, which still kept Akums close to the session peak during the morning update.
How much did Akums Drugs & Pharmaceuticals Ltd. rise today?
Ans. Akums Drugs & Pharmaceuticals Ltd. rose by Rs 24.4 on the day, equivalent to a 3.34% gain over the previous close of Rs 731.25. That move took the stock to a fresh one-year high of Rs 761.
What do today’s price levels show for Akums Drugs & Pharmaceuticals Ltd. Share Price?
Ans. The stock opened at Rs 720.35, which also marked the day low, and then climbed to Rs 761. Trading at Rs 755.65 near the high suggests strong intraday price action in the supplied session data.
What is the market capitalisation of Akums Drugs & Pharmaceuticals Ltd.?
Ans. Akums Drugs & Pharmaceuticals Ltd. had a market capitalisation of Rs 10,962.49 crore in the supplied data. That is far above the same-sector benchmark median of Rs 142.3 crore and average of Rs 472.15 crore.
Is Akums Drugs & Pharmaceuticals Ltd. richly valued compared with the Healthcare sector?
Ans. The stock’s P/E ratio is 40.09 against the sector median of 20.84, while its P/B ratio is 9.77 versus the sector median of 1.93. That places valuation above benchmark medians in the supplied comparison.
How profitable is Akums Drugs & Pharmaceuticals Ltd. based on the supplied data?
Ans. Akums reported ROE of 28.21% and ROCE of 26.35% in the supplied snapshot. Both are above the Healthcare sector median figures of 10.77% and 13.35%, showing stronger profitability than benchmark medians.
How does Akums compare with selected peers on valuation and returns?
Ans. Akums has a P/E of 40.09, lower than Beta Drugs at 66.92 and Sai Parenteral's at 181.97, while ROE of 28.21% is above Beta Drugs, Dr Agarwals and Sai Parenteral's in the supplied peer set.
What was the trading volume and turnover in Akums today?
Ans. The supplied session data showed current volume of 16,360 shares and turnover of Rs 1.24 crore. These figures confirm active trading interest on the day the stock touched its fresh 52-week peak.
Why is Akums Drugs & Pharmaceuticals Ltd. in focus today?
Ans. The stock is in focus because it hit a fresh 52-week high of Rs 761 while gaining 3.34% to Rs 755.65. Investors are also watching its Rs 10,962.49 crore market cap and strong return ratios.
Recent Articles

RIR Power Electronics Ltd. (RIR): RIR Power Electronics Share Price Rises 9.53% as Small Cap Stock Enters Top Gainers
11 August 2026

Nitin Castings Ltd. (NITINCAST): Nitin Castings Share Price Falls 10% Today; Micro Cap Stock in Focus
11 August 2026

Kilburn Engineering Ltd. (KLBRENG-B) Share Price Hits Fresh 52-Week Low
11 August 2026

DMCC Speciality Chem Q1 FY27 Results: Revenue Rs 253 Cr, PAT Rs 20 Cr and Key Highlights
11 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
RIR Power Electronics Ltd. (RIR): RIR Power Electronics Share Price Rises 9.53% as Small Cap Stock Enters Top Gainers
Nitin Castings Ltd. (NITINCAST): Nitin Castings Share Price Falls 10% Today; Micro Cap Stock in Focus
Kilburn Engineering Ltd. (KLBRENG-B) Share Price Hits Fresh 52-Week Low
DMCC Speciality Chem Q1 FY27 Results: Revenue Rs 253 Cr, PAT Rs 20 Cr and Key Highlights
Bajaj Steel Industries Q1 FY27 Results: Revenue Rs 120 Cr, Net Loss Rs 0.27 Cr and Key Highlights

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





